Human ESC/iPSC-based 'omics' and bioinformatics for translational research

Gerd A. Müller; Kirill V. Tarasov; Rebekah L. Gundry; Kenneth R. Boheler

doi:10.1016/j.ddmod.2012.02.003

Human ESC/iPSC-based 'omics' and bioinformatics for translational research

Gerd A. Müller, Kirill V. Tarasov, Rebekah L. Gundry, Kenneth R. Boheler

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.

Original language	English (US)
Pages (from-to)	e161-e170
Journal	Drug Discovery Today: Disease Models
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/j.ddmod.2012.02.003
State	Published - 2012
Externally published	Yes

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1016/j.ddmod.2012.02.003

Cite this

@article{44347a7546b846928a99de05fb4d18ec,

title = "Human ESC/iPSC-based 'omics' and bioinformatics for translational research",

abstract = "The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.",

author = "M{\"u}ller, {Gerd A.} and Tarasov, {Kirill V.} and Gundry, {Rebekah L.} and Boheler, {Kenneth R.}",

note = "Funding Information: The authors are supported by 4R00HL094708-03 (RLG), the Innovation Center at the Medical College of Wisconsin (RLG), the Intramural Research Program of the NIH , National Institute on Aging (KRB) and NIH Induced Pluripotent Stem Cell Center (NiPSCC) Pilot Study Award (KRB).",

year = "2012",

doi = "10.1016/j.ddmod.2012.02.003",

language = "English (US)",

volume = "9",

pages = "e161--e170",

journal = "Drug Discovery Today: Disease Models",

issn = "1740-6757",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Human ESC/iPSC-based 'omics' and bioinformatics for translational research

AU - Müller, Gerd A.

AU - Tarasov, Kirill V.

AU - Gundry, Rebekah L.

AU - Boheler, Kenneth R.

N1 - Funding Information: The authors are supported by 4R00HL094708-03 (RLG), the Innovation Center at the Medical College of Wisconsin (RLG), the Intramural Research Program of the NIH , National Institute on Aging (KRB) and NIH Induced Pluripotent Stem Cell Center (NiPSCC) Pilot Study Award (KRB).

PY - 2012

Y1 - 2012

N2 - The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.

AB - The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.

UR - http://www.scopus.com/inward/record.url?scp=84876690042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876690042&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2012.02.003

DO - 10.1016/j.ddmod.2012.02.003

M3 - Review article

C2 - 23682293

AN - SCOPUS:84876690042

SN - 1740-6757

VL - 9

SP - e161-e170

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

IS - 4

ER -

Human ESC/iPSC-based 'omics' and bioinformatics for translational research

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this